Search research articles
Contact Us
Filters
Showing results (11-20 of 144) with videos related to
Page
of 15
Sort By:
Future Oncology (London, England)
|
November 30, 2020
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
Lawrence Kasherman, Soha Ahrari, Stephanie Lheureux
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2019
The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers
Stephanie Lheureux, Mansoor Mirza, Robert Coleman
CA: a Cancer Journal for Clinicians
|
May 18, 2019
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Stephanie Lheureux, Marsela Braunstein, Amit M Oza
Expert Opinion on Pharmacotherapy
|
March 17, 2017
Niraparib for the treatment of ovarian cancer
Yada Kanjanapan, Stephanie Lheureux, Amit M Oza
Drug Design, Development and Therapy
|
April 3, 2018
Rucaparib: a novel PARP inhibitor for <i>BRCA</i> advanced ovarian cancer
Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza
Expert Opinion on Investigational Drugs
|
April 11, 2014
Recent and current Phase II clinical trials in endometrial cancer: review of the state of art
Stephanie Lheureux, Michelle Wilson, Helen J Mackay
Cancers
|
March 27, 2019
Tailoring Ovarian Cancer Treatment: Implications of <i>BRCA1/2</i> Mutations
Ainhoa Madariaga, Stephanie Lheureux, Amit M Oza
Current Opinion in Obstetrics & Gynecology
|
December 13, 2016
Treatment strategies for endometrial cancer: current practice and perspective
Yeh C Lee, Stephanie Lheureux, Amit M Oza
Cancer
|
June 1, 2026
Antibody-drug conjugates in gynecologic cancers
Arantzazu Barquin, Lawrence Kasherman, Stephanie Lheureux, et al.
Future Oncology (London, England)
|
June 2, 2018
The role of niraparib for the treatment of ovarian cancer
Josee-Lyne Ethier, Stephanie Lheureux, Amit M Oza
Page
of 15
Search research articles
Search
Showing results (11-20 of 144) with videos related to
Sort By:
Page
of 15
Future Oncology (London, England)
|
November 30, 2020
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer
Lawrence Kasherman, Soha Ahrari, Stephanie Lheureux
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 13, 2019
The DNA Repair Pathway as a Target for Novel Drugs in Gynecologic Cancers
Stephanie Lheureux, Mansoor Mirza, Robert Coleman
CA: a Cancer Journal for Clinicians
|
May 18, 2019
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Stephanie Lheureux, Marsela Braunstein, Amit M Oza
Expert Opinion on Pharmacotherapy
|
March 17, 2017
Niraparib for the treatment of ovarian cancer
Yada Kanjanapan, Stephanie Lheureux, Amit M Oza
Drug Design, Development and Therapy
|
April 3, 2018
Rucaparib: a novel PARP inhibitor for <i>BRCA</i> advanced ovarian cancer
Ilaria Colombo, Stephanie Lheureux, Amit Manulal Oza
Expert Opinion on Investigational Drugs
|
April 11, 2014
Recent and current Phase II clinical trials in endometrial cancer: review of the state of art
Stephanie Lheureux, Michelle Wilson, Helen J Mackay
Cancers
|
March 27, 2019
Tailoring Ovarian Cancer Treatment: Implications of <i>BRCA1/2</i> Mutations
Ainhoa Madariaga, Stephanie Lheureux, Amit M Oza
Current Opinion in Obstetrics & Gynecology
|
December 13, 2016
Treatment strategies for endometrial cancer: current practice and perspective
Yeh C Lee, Stephanie Lheureux, Amit M Oza
Cancer
|
June 1, 2026
Antibody-drug conjugates in gynecologic cancers
Arantzazu Barquin, Lawrence Kasherman, Stephanie Lheureux, et al.
Future Oncology (London, England)
|
June 2, 2018
The role of niraparib for the treatment of ovarian cancer
Josee-Lyne Ethier, Stephanie Lheureux, Amit M Oza
Page
of 15